A
AYA
vs
S
S&P/ASX 300
Over the past 12 months, AYA has significantly outperformed S&P/ASX 300, delivering a return of +293% compared to the S&P/ASX 300's +9% growth.
Stocks Performance
AYA vs S&P/ASX 300
Performance Gap
AYA vs S&P/ASX 300
Performance By Year
AYA vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Artrya Ltd
Glance View
Artrya Ltd. develops the Salix suite of products to address coronary artery disease (CAD). The company is headquartered in Perth, Western Australia. The company went IPO on 2021-11-26. The firm is focused on operating diagnostic imaging center. The company is primarily engaged in providing powered image-analysis software for coronary artery disease. Its non-invasive solution, Salix uses artificial intelligence (AI) to produce a 3D image and report that provides an accurate detection of coronary artery disease, including the presence of vulnerable plaque. Salix offers precision medicine for cardiac care. The company enables clinicians to triage patients and identify individuals at high risk of heart attack. The firm's cardiac-health report provides diagnostic support to radiologists and cardiologists.
